Microvesicles derived from mesenchymal stem cells inhibit acute respiratory distress syndrome-related pulmonary fibrosis in mouse partly through hepatocyte growth factor

Figure 3 Immunohistochemical detection of the effects of mesenchymal stromal cell-derived microvesicles on pulmonary and fibrosis-related indicators in acute respiratory distress syndrome pulmonary fibrosis mouse models. A: Hematoxylin and eosin staining of lung tissues from each group; B: Lung injury scores of pathological sections from each group; C: Masson staining of lung tissues from each group; D: Lung fibrosis scores of pathological sections from each group. ^aP < 0.05, vs the control group; ^bP < 0.05, vs the pulmonary fibrosis group; ^cP < 0.05, vs the mesenchymal stromal cell-derived microvesicles (MSC-MVs) group (n = 6). Control, acute respiratory distress syndrome (ARDS), pulmonary fibrosis, MSC, MSC-MVs and low hepatocyte growth factor (HGF)-MSC-MVs represent the control group, ARDS group, pulmonary fibrosis group, MSC group, MSC-MVs group and low HGF-MSC-MVs group, respectively.